Sarepta Therapeutics/$SRPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Ticker

$SRPT
Sector
Primary listing

Employees

1,372

SRPT Metrics

BasicAdvanced
$1.8B
-
-$0.60
0.45
-

What the Analysts think about SRPT

Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.

Bulls say / Bears say

Sarepta reported positive expression and functional data from its SRP-9003 gene therapy trial in limb-girdle muscular dystrophy Type 2E, with a 73% mean signal intensity and an 89% reduction in creatine kinase at the high dose, highlighting robust early efficacy (Reuters).
An FDA advisory panel backed accelerated approval for Sarepta’s SRP-9001 gene therapy for Duchenne muscular dystrophy, voting 8-6 that the company provided sufficient data to support the application, significantly increasing the likelihood of a May 2025 approval decision (Reuters).
The collaboration with Codiak Biosciences to develop exosome-based therapeutics for rare diseases could deliver up to $72.5 million in upfront and near-term licensing payments plus research funding, bolstering the pipeline and improving near-term cash flow (Reuters).
Commercial shipments of Elevidys were partially suspended following the deaths of two teenage patients, undermining physician and patient confidence and posing a significant reputational risk to Sarepta’s largest revenue generator (Reuters).
The company announced cost‐cutting measures, including halting a gene therapy study and implementing layoffs after a trial participant’s death, reflecting operational and financial strain on Sarepta’s resources (Reuters).
Sarepta’s share price has plunged nearly 90% year-to-date amid these safety and operational challenges, indicating sharply reduced investor confidence in the company’s near-term prospects (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

SRPT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SRPT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRPT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs